Javascript must be enabled to continue!
THE STUDIES ASSESSING STATIN IN CORONARY ATHEROSCLEROSIS PLAQUE PROGRESSION
View through CrossRef
Objectives
to assess the effect of therapy with statins on plaques.
Methods
searched eligible studies on PubMed, Embase databases and analysed them through Review Manager 5. The primary terminal point was the progression of plaque volume evaluated by intravascular ultrasound (IVUS). Weighted mean difference (WMD) was used as summary statistics for the results (continuous variables). Heterogeneity of the studies was analysed by Cochran's Q statistics. Sensitivity of the studies was analysed by stratified analysis according to the time of follow-up, the level of LDL-C and statins. All of biases of the studies were analysed by funnel plot.
Results
This meta-analysis adopted 19 studies from 14 papers. The total number of patients was 2631 and the mean follow-up was 18.7 months. That found a significant regression in coronary atherosclerotic plaque volume (WMD −6.59 mm3, 95% CI (−8.75 to −4.43) p<0.00001), with no significant heterogeneity across studies (p=0.78). Stratified analysis: Time of the follow-up >6 months (WMD −6.75 mm3, 95% CI (−9.10 to −4.40) p<0.00001) presented a trend for plaque regression through the follow-up ≤6 months (WMD −5.74 mm3, 95% CI (−11.20 to −0.28) p=0.04). Treatment with atorvastatin (WMD −6.83 mm3, 95% CI (−11.68, to −1.99) p=0.006) showed a stronger regression than rosuvastatin (WMD −6.41 mm3, 95% CI (−9.43 to −3.40) p<0.0001). At the end of follow-up, the LDL-C level on 80–100 mg/dl (WMD −8.88 mm3, 95% CI (−12.96 to −4.81) p<0.0001) reveal the strongest trend for plaque regression among all of the three LDL levels, including >80 mg/dl (−6.01 mm3, 95% CI (−8.82 to −3.21) p<0.0001), 80–100 mg/dl and <100 mg/dl (WMD −4.22 mm3, 95% CI (−10.27 to 1.82) p=0.017). Plaque volume remained essentially unchanged in patients not treated with statins (WMD 0.13 mm3, 95% CI (−4.42 to 4.68) p=0.96).
Conclusions
statin therapy, particularly when achieving the LDL level on 80–100 mg/dl, appears to promote a significant regression of coronary plaque volume as measured by IVUS.
Title: THE STUDIES ASSESSING STATIN IN CORONARY ATHEROSCLEROSIS PLAQUE PROGRESSION
Description:
Objectives
to assess the effect of therapy with statins on plaques.
Methods
searched eligible studies on PubMed, Embase databases and analysed them through Review Manager 5.
The primary terminal point was the progression of plaque volume evaluated by intravascular ultrasound (IVUS).
Weighted mean difference (WMD) was used as summary statistics for the results (continuous variables).
Heterogeneity of the studies was analysed by Cochran's Q statistics.
Sensitivity of the studies was analysed by stratified analysis according to the time of follow-up, the level of LDL-C and statins.
All of biases of the studies were analysed by funnel plot.
Results
This meta-analysis adopted 19 studies from 14 papers.
The total number of patients was 2631 and the mean follow-up was 18.
7 months.
That found a significant regression in coronary atherosclerotic plaque volume (WMD −6.
59 mm3, 95% CI (−8.
75 to −4.
43) p<0.
00001), with no significant heterogeneity across studies (p=0.
78).
Stratified analysis: Time of the follow-up >6 months (WMD −6.
75 mm3, 95% CI (−9.
10 to −4.
40) p<0.
00001) presented a trend for plaque regression through the follow-up ≤6 months (WMD −5.
74 mm3, 95% CI (−11.
20 to −0.
28) p=0.
04).
Treatment with atorvastatin (WMD −6.
83 mm3, 95% CI (−11.
68, to −1.
99) p=0.
006) showed a stronger regression than rosuvastatin (WMD −6.
41 mm3, 95% CI (−9.
43 to −3.
40) p<0.
0001).
At the end of follow-up, the LDL-C level on 80–100 mg/dl (WMD −8.
88 mm3, 95% CI (−12.
96 to −4.
81) p<0.
0001) reveal the strongest trend for plaque regression among all of the three LDL levels, including >80 mg/dl (−6.
01 mm3, 95% CI (−8.
82 to −3.
21) p<0.
0001), 80–100 mg/dl and <100 mg/dl (WMD −4.
22 mm3, 95% CI (−10.
27 to 1.
82) p=0.
017).
Plaque volume remained essentially unchanged in patients not treated with statins (WMD 0.
13 mm3, 95% CI (−4.
42 to 4.
68) p=0.
96).
Conclusions
statin therapy, particularly when achieving the LDL level on 80–100 mg/dl, appears to promote a significant regression of coronary plaque volume as measured by IVUS.
Related Results
GAMBARAN PROFIL LIPID PADA PASIEN PENYAKIT JANTUNG KORONER
GAMBARAN PROFIL LIPID PADA PASIEN PENYAKIT JANTUNG KORONER
Abstract: Coronary Heart Disease is a heart disease caused by the narrowing of the coronary arteries, which then disturbs the flow of blood to the myocardium. The result of SKRT do...
GW24-e2475 Relationship between intravascular ultrasonic plaque morphology and quantitative acoustic densitometry of carotid plaque in patients with coronary artery disease
GW24-e2475 Relationship between intravascular ultrasonic plaque morphology and quantitative acoustic densitometry of carotid plaque in patients with coronary artery disease
Objectives
This study was designed to investigate the relationship between intravascular ultrasonic plaque morphology and quantitative acoustic densitometry by in...
A Link Between Hypercholesterolemia and Chronic Lymphocytic Leukemia
A Link Between Hypercholesterolemia and Chronic Lymphocytic Leukemia
Abstract
Background
Dyslipidemia and metabolic syndrome are risk factors for cancer, and clinically aggressive CLL cells are believed to rely on lipid...
Abstract P1-15-03: Assessing the association of statins with clinical outcomes in women with breast cancer
Abstract P1-15-03: Assessing the association of statins with clinical outcomes in women with breast cancer
Abstract
Background: A growing number of studies are claiming lipid-lowering medications (LLMs) primarily statins have anticancer properties to inhibit proliferation...
Predictors of statin adherence in primary care using real-world data
Predictors of statin adherence in primary care using real-world data
Abstract
Purpose
The objective of this study was to identify predictors of statin adherence in the primary and secondary preven...
Fat-Free Mass and Fasting Glucose Values in Patients with and without Statin Therapy Assigned to Age Groups between <60 and >75 Years
Fat-Free Mass and Fasting Glucose Values in Patients with and without Statin Therapy Assigned to Age Groups between <60 and >75 Years
<b><i>Objective:</i></b> The aging-associated changes in body composition result in an increased cardiometabolic risk. A tremendous reduction of cardiovascu...
1228-P: Comparison between Combination of Low- or Moderate-Intensity Statin with Ezetimibe and High-Intensity Statin Monotherapy for Primary Prevention of Cardiovascular Disease and All-Cause Mortalities in Patients with Type 2 Diabetes—A Propensity-Match
1228-P: Comparison between Combination of Low- or Moderate-Intensity Statin with Ezetimibe and High-Intensity Statin Monotherapy for Primary Prevention of Cardiovascular Disease and All-Cause Mortalities in Patients with Type 2 Diabetes—A Propensity-Match
Background and Aims: Here, we compared the effects of combination therapy of low- or moderate-statin with ezetimibe and high-intensity statin monotherapy in patients with type 2 di...
Statins Are Associated with Improved 28-day Mortality in Patients Hospitalized with SARS-CoV-2 Infection
Statins Are Associated with Improved 28-day Mortality in Patients Hospitalized with SARS-CoV-2 Infection
Abstract
Background
Statins may be protective in viral infection and have been proposed as treatment in severe acute respirator...

